Skip to content
Screener

Alnylam Pharmaceuticals ALNY Q1 2025 earnings

Reported May 1, 2025 · Before market open

Revenue$594.2MBeat by $9.0M
EPS-$0.01Beat by $0.88
Revenue estimate$585.1M
EPS estimate-$0.89

Next report

Oct 29, 2026 (in 2 months)
Revenue estimate$1.4B
EPS estimate$2.19

Financials

Q1 2025

Income statement

See full
Revenue$594.2M+20.2%
Gross profit$524.0M+19.2%
Operating income$18.1M+142%
Net income-$18.3M+72.3%
EPS (diluted)-$0.14+73.1%

Balance sheet

See full
Cash & equivalents$1.0B+49.3%
Total debt$276.1M-1.2%
Total equity$115.4M+153%
Total assets$4.2B+10.2%

Cash flow

See full
Operating cash flow-$118.3M-45.1%
CapEx$9.0M-30.9%
Free cash flow-$127.3M-34.7%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$34.95B+85.7%
Enterprise value$34.2B+85.7%
P/S14.9×+5.5×

Profitability

See full
Gross margin86.3%+0.3pp
Operating margin-4.9%-1.5pp
Net margin-9.8%-2.8pp
FCF margin-3.2%—

Returns & leverage

See full
Debt / equity2.4×—
Current ratio3×-0.1×

Segments

By product

See full
AMVUTTRA$310.0M—
GIVLAARI$67.0M—
ONPATTRO$49.5M—
OXLUMO$42.1M—

FAQ

When did Alnylam Pharmaceuticals report Q1 2025 earnings?
Alnylam Pharmaceuticals (ALNY) reported Q1 2025 earnings on May 1, 2025 before market open.
What were Alnylam Pharmaceuticals's Q1 2025 revenue and EPS?
Alnylam Pharmaceuticals reported revenue of $594.2M and eps of $-0.01 for Q1 2025.
Did Alnylam Pharmaceuticals beat estimates in Q1 2025?
Revenue beat the consensus estimate of $585.1M by $9.0M. EPS beat the consensus estimate of $-0.89 by $0.88.
How did Alnylam Pharmaceuticals's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 20.2% from $494.3M a year earlier and eps grew 93.8% from $-0.16.
Where can I find Alnylam Pharmaceuticals's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001178670-25-000050) and the 10-Q periodic report (0001178670-25-000052) directly on SEC EDGAR. The filing index links above go to sec.gov.